TY - JOUR
T1 - Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma
AU - Danylesko, Ivetta
AU - Shouval, Roni
AU - Shem-Tov, Noga
AU - Yerushalmi, Ronit
AU - Jacoby, Elad
AU - Besser, Michal J.
AU - Shimoni, Avichai
AU - Davidson, Tima
AU - Beider, Katia
AU - Mevorach, Dror
AU - Fried, Shalev
AU - Nagler, Arnon
AU - Avigdor, Abraham
N1 - Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2021/5
Y1 - 2021/5
N2 - We present three patients with aggressive non-Hodgkin’s B-cell lymphoma (NHL) who received anti-CD19 chimeric antigen receptor T (CAR T) cells therapy after failure of several lines of chemotherapy that developed pseudo-progression. One-week clinical and radiological findings were consistent with tumor progression. Positron emission tomography-computed tomography (PET-CT) at 1 month post CAR T cells administration was consistent with treatment response. The rapid tumor growth and subsequent resolution are suggestive of tumor pseudo-progression mediated secondary to infiltration and immune activation of CAR T cells. Overall, 56 adult patients with NHL were enrolled in a phase 1b/2 in house clinical study with CD19 CAR T cells. Out of them 22/56 patients progressed as per PET-CT the 1 month post CAR T cells. In 14 patients, signs of progression started 7–10 days after CAR T cells infusion. In 11/14 patients, it was true progression, while in 3 it was pseudo-progression. Additional studies are warranted to describe the extent of this phenomenon and evaluate correlation with the CAR T activity and long-term disease control.
AB - We present three patients with aggressive non-Hodgkin’s B-cell lymphoma (NHL) who received anti-CD19 chimeric antigen receptor T (CAR T) cells therapy after failure of several lines of chemotherapy that developed pseudo-progression. One-week clinical and radiological findings were consistent with tumor progression. Positron emission tomography-computed tomography (PET-CT) at 1 month post CAR T cells administration was consistent with treatment response. The rapid tumor growth and subsequent resolution are suggestive of tumor pseudo-progression mediated secondary to infiltration and immune activation of CAR T cells. Overall, 56 adult patients with NHL were enrolled in a phase 1b/2 in house clinical study with CD19 CAR T cells. Out of them 22/56 patients progressed as per PET-CT the 1 month post CAR T cells. In 14 patients, signs of progression started 7–10 days after CAR T cells infusion. In 11/14 patients, it was true progression, while in 3 it was pseudo-progression. Additional studies are warranted to describe the extent of this phenomenon and evaluate correlation with the CAR T activity and long-term disease control.
UR - http://www.scopus.com/inward/record.url?scp=85096988345&partnerID=8YFLogxK
U2 - 10.1038/s41409-020-01156-y
DO - 10.1038/s41409-020-01156-y
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 33268830
AN - SCOPUS:85096988345
SN - 0268-3369
VL - 56
SP - 1134
EP - 1143
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 5
ER -
